NRX Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NRX Pharmaceuticals, Inc. (NRXP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$3.28 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2024-05-14
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$3.28M.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$3.55M, a 128.17% decline year-over-year.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $12.60M, a 10.38% increase year-over-year.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $11.41M.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$15.46M.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$7.55M, a 129.33% decline from fiscal 2021.
- NRX Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $25.75M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$3.28M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | -$15.46M 10-K · filed 2024-03-29 | |||
| 2023-09-30 | -$11.15M 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | -$5.08M 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | -$3.55M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$7.55M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$9.36M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$3.06M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $12.60M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $25.75M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $37.02M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $11.53M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $11.41M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |